Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023 Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post- AB-729 treatment AB-161 provides robust anti-HBV...

Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023 Two oral presentations scheduled for Thursday, April 27, 2023 WARMINSTER, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical...